使用89Zr标记达雷妥尤单抗在小鼠淋巴瘤模型中进行CD38免疫PET显像
研究用89Zr标记达雷妥尤单抗(89Zr-Df-daratumumab)在小鼠淋巴瘤模型中无创评估CD38表达。Ramos细胞CD38表达最高,注射后120小时肿瘤摄取高达26.6 ± 8.0 %ID/g,HBL-1仅6.6 ± 2.9 %ID/g(n = 4);非特异性对照89Zr-Df-IgG在Ramos模型仅4.3 ± 0.8 %ID/g。作者认为该显像剂是未来临床应用中CD38阳性血液病(如多发性骨髓瘤)有前景的显像剂。
要点
- Ramos细胞CD38表达最高,HBL-1最低。
- 注射后120小时Ramos肿瘤摄取高达26.6 ± 8.0 %ID/g(n = 4)。
- 作者认为该显像剂是CD38阳性血液病有前景的显像剂。
核心结论
- 作者认为89Zr-Df-daratumumab是未来临床应用中CD38阳性血液病(如多发性骨髓瘤)有前景的显像剂。
研究设计与样本
- 研究用89Zr(半衰期78.4小时)经去铁胺(Df)偶联标记达雷妥尤单抗,在五种淋巴瘤细胞系中筛选CD38表达。
- 体外用流式细胞术和细胞结合实验检测标记或偶联达雷妥尤单抗与CD38的结合能力。
- 在注射89Zr-Df-daratumumab后进行PET显像和生物分布研究评估CD38表达。
- 在Ramos模型中评估89Zr-Df-IgG作为非特异性对照组。
- 最后用组织学分析验证肿瘤组织中CD38表达。
主要发现
- 蛋白质印迹(WB)筛选发现Ramos细胞系CD38表达最高,HBL-1细胞系表达最低。
- Df偶联和89Zr标记的达雷妥尤单抗与Ramos细胞显示相似的高结合亲和力。
- 89Zr-Df-daratumumab PET显像显示注射后120小时Ramos肿瘤摄取高达26.6 ± 8.0 %ID/g,HBL-1仅6.6 ± 2.9 %ID/g(n = 4)。
- 89Zr-Df-IgG在Ramos模型注射后120小时肿瘤摄取低,仅4.3 ± 0.8 %ID/g。
- 离体生物分布研究与显像结果趋势相似,肿瘤组织免疫荧光染色验证Ramos的CD38表达高于HBL-1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with 89Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic. METHODS: Daratumumab was radiolabeled with 89Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of 89Zr-Df-daratumumab. 89Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis. RESULTS: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and 89Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of 89Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally, 89Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1. CONCLUSIONS: The role of 89Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications.
引用
- Kang L, Jiang D, England CG, et al. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018. PMID: 29450576. doi:10.1007/s00259-018-3941-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。